Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin for Post-stroke Cognition
NCT02810392Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2016
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human insulin in post-stroke cognitive impairment (PSCI) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Composite of Memory t Scores at 6 weeks, Composite of Executive Function t/z Scores at 6 weeks and 1 more. Started Apr 2016; status: completed.
02
Drugs
human insulin
03
Conditions
post-stroke cognitive impairment (PSCI)
Beyond the preview
Go deeper on NCT02810392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810392.